NextCell Pharma

Eric Gustafsson has a master's degree in economics and finance and a broad and versatile experience in finance, manufacturing and business development from the international CDMO and pharmaceutical industries. He has held several senior positions within Recipharm, including General Manager, Interim CFO for part of the European business that was divested to a new owner, and as Senior Commercial Manager in Recipharm's OSD segment. Prior to that, he has held leading financial roles at Cobra Biologics, among others. Earlier in his career, he worked in auditing at KPMG.

His experience covers both strategic and operational responsibilities across manufacturing, finance, M&A and commercial development. With a deep understanding of regulated environments, quality requirements and complex production flows, Eric is well positioned to contribute to NextCell's continued growth and transition toward industrial scale operations.

"Eric has an exceptional breadth, combining financial rigour with hands-on operational experience from manufacturing and business development within the CDMO sector. This is exactly the kind of profile we need as NextCell enters its next phase of increased industrial maturity and international expansion," says Mathias Svahn, CEO of NextCell Pharma AB.

Eric will assume his position on 15 December 2025, succeeding Patrik Fagerholm, who is leaving the company for a new role outside the group.